A double-blind group comparative trial of nedocromil sodium and placebo in the management of bronchial asthma.
A 3-month double-blind group comparative trial of nedocromil sodium (4 mg twice daily) and placebo was carried out in 30 adult asthmatic patients maintained on bronchodilator therapy. Fifteen patients received each treatment. Subjective (asthma symptoms and severity) and objective (lung function and use of concomitant medication) variables were measured to monitor the response to trial treatments. Significant differences in favour of nedocromil sodium for night-time asthma, daytime asthma, cough, daytime bronchodilator use and clinic assessment of forced expiratory volume during the first second of expiration were observed by week 4 of the trial. The diurnal variation in peak expiratory flow rate was reduced in the nedocromil sodium treated patients. There were no serious adverse reactions and no treatment related changes in haematological findings, blood biochemistry or urinalysis.
Fairfax
A J
AJ
Department of Thoracic Medicine, Staffordshire General Infirmary, UK.
Allbeson
M
M
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007239:Infections / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D017835:Nedocromil; D010366:Peak Expiratory Flow Rate; D010919:Placebos; D011804:Quinolines / Q000627:therapeutic use*; D012135:Respiratory Sounds / Q000209:etiology / Q000503:physiopathology; D013896:Thoracic Diseases / Q000139:chemically induced; D014797:Vital Capacity
D001993:Bronchodilator Agents; D010919:Placebos; D011804:Quinolines; D017835:Nedocromil